Back to results
US 7,402,556 B2Granted
Prodrugs activated by plasmin and their use in cancer chemotherapy
AssigneeMedarex, Inc.
InventorsAndré Trouet, Vincent Dubois, Alexandre Passioukov
Life of this patent
Estimating the term…
Abstract
The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
Claims24
A pharmaceutical composition comprising:
- (1) A compound comprising:
- (a) a therapeutic agent capable of entering a target tumor cell, wherein said therapeutic agent is daunorubicin or doxorubicin and plasmin is present in the extracellular vicinity of the target tumor cell;
- (b) an oligopeptide having the formula (AAx)m-(AAy)n (SEQ ID NO:1) wherein:
- (AAx)m is a plasmin substrate and each AAx independently represents an amino acid;
- each AAy independently represents an amino acid selected from the group consisting of Ile, Leu, Phe, and Val;
- m is an integer from 2-4;
- and n is an integer from 1-2;
- (c) a stabilizing group;
- and
- (d) optionally, a linker group not cleavable by plasmin;
- wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide;
- wherein the stabilizing group hinders cleavage of the oligopeptide by enzymes present in whole blood;
- and wherein the compound is cleaved by plasmin under physiological conditions;
- and
- (2) a pharmaceutically acceptable carrier.
12 more elements
A compound comprising:
- (1) a therapeutic agent capable of entering a target tumor cell, wherein said therapeutic agent is daunorubicin or doxorubicin and plasmin is present in the extracellular vicinity of the target tumor cell;
- (2) an oligopeptide having the formula X-Y, where X is a plasmin peptide substrate of 2-4 amino acids and Y is a peptide comprising 1-2 amino acids each independently selected from the group consisting of Ile, Leu, Phe, and Val;
- (3) a stabilizing group;
- and
- (4) optionally, a linker group not cleavable by plasmin;
- wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide;
- wherein the stabilizing group hinders cleavage of the oligopeptide by enzymes present in whole blood;
- and wherein the compound is cleavable by plasmin.
5 more elements
A method for treating a patient for a tumor, the method comprising administering to the patient a compound comprising:
- (1) a therapeutic agent capable of entering a target tumor cell, wherein said therapeutic agent is daunorubicin or doxorubicin;
- (2) an oligopeptide having the formula (AAx)m(AAy)n(SEQ ID NO:1) wherein:
- (AAx)n is a plasmin substrate and each AAx independently represents an amino acid;
- each AAy independently represents an amino acid selected from the group consisting of Ile, Leu, Phe, and Val;
- m is an integer from 2-4;
- and n is an integer from 1-2;
- (3) a stabilizing group;
- and
- (4) optionally, a linker group not cleavable by plasmin;
- wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide;
- wherein the stabilizing group hinders cleavage of the oligopeptide by enzymes present in whole blood;
- wherein plasmin is present in the extracellular vicinity of the target tumor cell and wherein the compound is cleaved by plasmin under physiological conditions.
9 more elements
Dependencies are inferred from the claim text.